Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Show more

Location: 131 Dartmouth Street, Boston, MA, 02116, United States | Website: https://www.adicetbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

67.45M

52 Wk Range

$0.45 - $1.57

Previous Close

$0.88

Open

$0.86

Volume

538,165

Day Range

$0.78 - $0.89

Enterprise Value

-42.15M

Cash

125M

Avg Qtr Burn

-24.53M

Insider Ownership

2.79%

Institutional Own.

61.26%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.